Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2023

27-08-2023 | Hepatobiliary Tumors

Circulating Tumor Cells are an Independent Risk Factor for Poor Prognosis in Patients with Gallbladder Adenocarcinoma

Authors: Cheng Yan, MD, Yangyan Xiao, MD, Weichang Zhang, MD, Yuxin Sun, MD, Youjun Lin, MD, Wenwu Cai, MD

Published in: Annals of Surgical Oncology | Issue 13/2023

Login to get access

Abstract

Background

The study aimed to evaluate the prognostic impact of circulating tumor cells (CTCs) in patients with gallbladder adenocarcinoma after resection.

Materials and Methods

Between January 2018 and January 2021, 101 consecutive patients with gallbladder adenocarcinoma were included. CTCs were detected and enumerated using the CanPatrol® technique. The follow-up period ended in January 2023. The cancer-specific survival (CSS) and disease-free survival (DFS) were calculated using log-rank and Cox regression analyses.

Results

CTCs were detected positively in 61.54% (8/13) of the patients in the non-operation group and 13.64% (12/88) in the operation group. In the operation group, the median CSS for CTCs-positive and CTCs-negative patients was 5.0 and 9.5 months (P < 0.001), respectively, and DFS was 2.8 and 5.0 months at stage III (P < 0.001), respectively. In the non-operation group, the median CSS for CTCs-positive and CTCs-negative patients was 3.5 and 6.5 months (P = 0.0031), respectively. The median CSS for CTCs-positive patients in the operation group was similar to that in the non-operation group (P = 0.67). Multivariate analyses showed that positive CTCs was an independent risk factor for poor CSS (HR 0.066, 95% CI 0.021–0.206, P < 0.001) as well as lymph infiltration (HR 0.320, 95% CI 0.110–0.930, P = 0.036), without R0 curative resection (HR 7.520, 95% CI 2.100–26.931, P = 0.002), and without adjuvant chemotherapy (HR 7.730, 95% CI 2.416–24.731, P < 0.001).

Conclusion

Positive CTCs was an independent predictor of poor prognosis after resection in patients with gallbladder adenocarcinoma. Preoperative detection of CTCs may play an important guiding role in formulating treatment strategies for these patients.
Appendix
Available only for authorised users
Literature
1.
2.
Goldin RD, Roa JC. Gallbladder cancer: a morphological and molecular update. Histopathology. 2009;55:218–29.CrossRefPubMed
3.
Kakaei F, Beheshtirouy S, Nejatollahi SM, Zarrintan S, Mafi MR. Surgical treatment of gallbladder carcinoma: a critical review. Updates Surg. 2015;67:339–51.CrossRefPubMed
4.
Cziupka K, Partecke LI, Mirow L, et al. Outcomes and prognostic factors in gallbladder cancer: a single-centre experience. Langenbecks Arch Surg. 2012;397:899–907.CrossRefPubMed
5.
Lazcano-Ponce EC, Miquel JF, Muñoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.CrossRefPubMed
6.
Mekeel KL, Hemming AW. Surgical management of gallbladder carcinoma: a review. J Gastrointest Surg. 2007;11:1188–93.CrossRefPubMed
7.
Levy AD, Murakata LA, Rohrmann CA Jr. Gallbladder carcinoma: radiologic- pathologic correlation. Radiographics. 2001; 21: 295-314; questionnaire, 549–555.
8.
Butte JM, Matsuo K, Gönen M, et al. Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg. 2011;212:50–61.CrossRefPubMed
9.
Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Med J Aust. 1869;14:146–9.
10.
Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol. 2009;6(6):339–51.CrossRefPubMed
11.
12.
13.
Brown HK, Tellez-Gabriel M, Cartron P-F, Vallette FM, Heymann M-F, Heymann D. Characterization of circulating tumor cells as a reflection of the tumor heterogeneity: Myth or reality? Drug Discov Today. 2019;24(3):763–72.CrossRefPubMed
14.
Zieglschmid V, Hollmann C, Böcher O. Detection of disseminated tumor cells in peripheral blood. Crit Rev Clin Lab Sci. 2005;42(2):155–96.CrossRefPubMed
15.
Cheng BR, Tong GL, Wu X, et al. Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer. Onco Targets Ther. 2019;25(12):7887–96.CrossRef
16.
Amin MB, Edge SB, Greene FL, et al editors. AJCC cancer staging manual. New York: Springer; 2017.
17.
18.
Awasthi NP, Kumari S, Neyaz A, et al. EpCAM-based Flow cytometric detection of circulating tumor cells in gallbladder carcinoma cases. Asian Pac J Cancer Prev. 2017;18(12):3429–37.PubMedPubMedCentral
19.
Wang YP, Yuan ZQ, Zhu SB, et al. The longitudinal change of circulating tumor cell during chemotherapy and its correlation with disease features, treatment response and survival profile of advanced gallbladder carcinoma. Am J Transl Res. 2021;13(12):13590–8.PubMedPubMedCentral
20.
Zhang XZ, Li L, Zhang M, et al. Intelligent recognition of CTCs from gallbladder cancer by ultrasensitive electrochemical cytosensor and diagnosis of chemotherapeutic resistance. Biosens Bioelectron. 2023;228:115183.CrossRefPubMed
21.
Zhang KL, Gao XM, Qin LX. The biological characteristics and signifcance of circulating tumor cells in patients with solid malignancies. Fudan Univ J Med Sci. 2016;43(1):94–8.
22.
Mostert B, Sleijfer S, Foekens JA, Gratama JW. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev. 2009;35:463–74.CrossRefPubMed
23.
Cristofanilli M, Budd GT, Ellis MJ, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351(8):781–91.CrossRefPubMed
24.
Scher HI, Jia XY, de Bono JS, et al. Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009;10(3):233–9.CrossRefPubMedPubMedCentral
25.
Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol. 2009;20(7):1223–9.CrossRefPubMed
26.
Duan GC, Zhang XP, Wang HE, et al. Circulating tumor cells as a screening and diagnostic marker for early-stage non-small cell lung cancer. Onco Targets Ther. 2020;13:1931–9.CrossRefPubMedPubMedCentral
27.
Ye XP, Li GH, Han CY, et al. Circulating tumor cells as a potential biomarker for postoperative clinical outcome in HBV-related hepatocellular carcinoma. Cancer Manag Res. 2018;10:5639–47.CrossRefPubMedPubMedCentral
28.
Okubo K, Uenosono Y, Arigami T, et al. Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Eur J Surg Oncol. 2017;43:1050–5.CrossRefPubMed
29.
Cabel L, Proudhon C, Gortais H, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017;22:421–30.CrossRefPubMed
30.
Khoja L, Backen A, Sloane R, et al. A pilot study to explore circulating tumor cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106:508–16.CrossRefPubMed
31.
Poruk KE, Valero V 3rd, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. Ann Surg. 2016;264:1073–81.CrossRefPubMed
32.
Fischer JC, Niederacher D, Topp SA, et al. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients. Proc Natl Acad Sci USA. 2013;110:16580–5.CrossRefPubMedPubMedCentral
33.
34.
van Dalum G, Stam GJ, Scholten LFA, et al. Importance of circulating tumor cells in newly diagnosed colorectal cancer. Int J Oncol. 2015;46:1361–8.CrossRefPubMed
35.
36.
Metadata
Title
Circulating Tumor Cells are an Independent Risk Factor for Poor Prognosis in Patients with Gallbladder Adenocarcinoma
Authors
Cheng Yan, MD
Yangyan Xiao, MD
Weichang Zhang, MD
Yuxin Sun, MD
Youjun Lin, MD
Wenwu Cai, MD
Publication date
27-08-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2023
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14231-7

Other articles of this Issue 13/2023

Annals of Surgical Oncology 13/2023 Go to the issue

Thoracic Oncology

Effect of Early Versus Late Oral Feeding on Postoperative Complications and Recovery Outcomes for Patients with Esophageal Cancer: A Systematic Evaluation and Meta-Analysis

ASO Author Reflections

ASO Author Reflections: Contemporary Management of Low-Grade Appendiceal Mucinous Neoplasms

Translational Research

Effects of TRPV2 on the Expression of PD-L1 and Its Binding Ability to PD-1 in Gastric Cancer

Translational Research

Machine-Learning Algorithms Using Systemic Inflammatory Markers to Predict the Oncologic Outcomes of Colorectal Cancer After Surgery

ASO Visual Abstract

ASO Visual Abstract: Lymph Node Metastases and Associated Recurrence-Free Survival in Microsatellite Stable and Unstable Colon Cancer

Thoracic Oncology

Quantitative Evaluation of Periodontitis for Predicting the Occurrence of Postoperative Pneumonia After Oncologic Esophagectomy